Informed-money record
ATYR · aTYR PHARMA INC
Disclosed informed-money activity on this name over the last 12 months — corporate insiders, institutions, and members of Congress, from public-domain SEC and congressional filings. A dated factual record with receipts; interpretation is yours.
Bullish filings
3
Bearish filings
3
Named actors
4
Disclosed $ (bull / bear)
$962K / $6K
Recent disclosures
6 of 6 in the window · linked to source| Date | Who | What | Disclosed $ | Receipt |
|---|---|---|---|---|
| 2026-05-27 | Director SCHIMMEL PAUL | bought | $50K | SEC ↗ |
| 2026-02-04 | General Counsel DENYES NANCY | sold | $1K | SEC ↗ |
| 2026-02-04 | Chief Financial Officer Broadfoot Jill Marie | sold | $2K | SEC ↗ |
| 2026-02-04 | President and CEO Shukla Sanjay | sold | $4K | SEC ↗ |
| 2025-10-09 | Director SCHIMMEL PAUL | bought | $299K | SEC ↗ |
| 2025-10-08 | Director SCHIMMEL PAUL | bought | $614K | SEC ↗ |
Want the read, not just the record?
Members see how notable each move is, whether the actor's track record validates, cross-source convergence, and alerts on this name.
Create a free account →Dispute or correct this record
Events dated by when the activity occurred (a trade's transaction date; a notice, stake, or announcement at its filing date); the linked filing is the authoritative record. Directional public-domain disclosures only. Descriptive, not investment advice. Methodology · Today's notable signals